Follow‐up of Patients with “Superficial” Transitional Cell Carcinoma of the Bladder: the Case for a Change in Policy

British Journal of Urology

Volumn 72, Issue 2, 1993, Pages 135-142

  ABEL, P D ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FOLLOW UP; HUMAN; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA;

BLADDER NEOPLASMS; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; FOLLOW-UP STUDIES; HUMAN; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; UROGRAPHY;

EID: 0027179657     PISSN: 00071331     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.1993.tb00674.x     Document Type: Review

References (41)

1. Should pT1 transitional cell cancers of the bladder still be classified as superficial?
2. Differing interpretations by pathologists of the pT category and grade of transitional cell cancer of the bladder
3. The significance of lamina propria invasion on the prognosis of patients with bladder tumors
4. Estimating the financial savings from maintaining the level of acute services with fewer hospital beds
5. The pT1 G3 bladder tumour
6. The dangers of a long urological waiting list
7. Intravenous urography in the follow‐up of carcinoma of the bladder
8. The origin of invasive carcinoma of the bladder
9. TNM (1978) in bladder cancer: use and abuse
10. Longitudinal study of patients with bladder cancer: factors associated with disease recurrence and progression
11. Transitional cell cancer: upper tracts and bladder
12. Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection
13. The value of tumour‐associated tissue inflammatory reaction in primary superficial bladder cancer
14. The pathogenesis of bladder cancer
15. Benign papilloma or papillary carcinoma of the bladder?
16. Survival with bladder cancer: associations of treatment delay, type of surgeon and modality of treatment
17. Can efficiency of follow‐up for superficial bladder cancer be increased?
18. Upper tract tumours following cystectomy for bladder cancer. Is routine intravenous urography worthwhile?
19. Superficial bladder cancer: progression and recurrence
20. Superficial bladder cancer treated with Bacillus Calmette‐Guérin: a multivariate analysis of factors affecting tumor progression
21. Infiltrating carcinoma of the bladder; relation of depth of penetration of the bladder wall to incidence of local extension and metastasis
22. Mode of presentation of invasive bladder cancer: reassessment of the problem
23. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder
24. Histopathological “self control” in transurethral resection of bladder tumours
25. Presenting symptoms, treatment delay and survival in bladder cancer
26. Rationalisation of follow‐up in patients with non‐invasive bladder tumours
27. Long‐term follow‐up of intravesical Epodyl therapy for superficial bladder cancer
28. Intravesical therapy in the management of superficial transitional cell carcinoma of the bladder: the experience of the EORTC GU group
29. Muscle‐invasive bladder cancer: does it arise de novo or from pre‐existing superficial disease?
30. Analysis of the performance of pathologists in the grading of bladder tumors
31. Prognostic factors for recurrence and follow‐up policies in the treatment of superficial bladder cancer
32. Bladder carcinoma as a systemic disease
33. Interpretation of biopsies of “normal” urothelium in patients with superficial bladder cancer
34. Current state of classification and staging of bladder cancer
35. Where is the wisdom …?
36. Rationale for intensive intravesical chemotherapy for superficial bladder cancer
37. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer
38. Should the follow‐up of patients with bladder cancer include routine excretory urography?
39. Toward the rational management of bladder cancer: an overview